Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need

3 years ago

Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open…

PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants

3 years ago

PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming…

Avalo Reports 2022 Financial Results and Provides Business Updates

3 years ago

Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second…

PDS Biotech to Participate in Cantor’s Future of Oncology Virtual Symposium 

3 years ago

FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a…

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

3 years ago

Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced…

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease

3 years ago

TORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty…

Healthcare Triangle Announces $3 Million Cloud DevOps Managed Services Agreement

3 years ago

Company’s HITRUST-certified Cloud DevOps Managed Services enable new customer to quickly adopt and deploy cloud solutions in a secure, compliant,…

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

3 years ago

Presentations highlight utility of this advanced hernia reinforcement material for robotic proceduresMALVERN, Pa., March 29, 2023 (GLOBE NEWSWIRE) -- TELA…

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

3 years ago

BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives…